TY - JOUR
T1 - Global alignment of immunization safety assessment in pregnancy – The GAIA project
AU - for the GAIA project participants
AU - Bonhoeffer, Jan
AU - Kochhar, Sonali
AU - Hirschfeld, Steven
AU - Heath, Paul T.
AU - Jones, Christine E.
AU - Bauwens, Jorgen
AU - Honrado, Ángel
AU - Heininger, Ulrich
AU - Muñoz, Flor M.
AU - Eckert, Linda
AU - Steinhoff, Mark
AU - Black, Steven
AU - Padula, Michael
AU - Sturkenboom, Miriam
AU - Buttery, Jim
AU - Pless, Robert
AU - Zuber, Patrick
N1 - Publisher Copyright:
© 2016
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Immunization in pregnancy provides a promising contribution to globally reducing neonatal and under-five childhood mortality and morbidity. Thorough assessment of benefits and risks for the primarily healthy pregnant women and their unborn babies is required. The GAIA project was formed in response to the call of the World Health Organization for a globally concerted approach to actively monitor the safety of vaccines and immunization in pregnancy programs. GAIA aims to improve the quality of outcome data from clinical vaccine trials in pregnant women with a specific focus on the needs and requirements for safety monitoring in LMIC. In the first year of the project, a large and functional network of experts was created. The first outputs include a guidance document for clinical trials of immunization in pregnancy, a basic data collection guide, ten case definitions of key obstetric and neonatal health outcomes, an ontology of key terms and a map of pertinent disease codes. The GAIA Network is designed as an open and growing forum for professionals sharing the GAIA vision and aim. Based on the initial achievements, tools and services are developed to support investigators and strengthen immunization in pregnancy programs with specific focus on LMIC.
AB - Immunization in pregnancy provides a promising contribution to globally reducing neonatal and under-five childhood mortality and morbidity. Thorough assessment of benefits and risks for the primarily healthy pregnant women and their unborn babies is required. The GAIA project was formed in response to the call of the World Health Organization for a globally concerted approach to actively monitor the safety of vaccines and immunization in pregnancy programs. GAIA aims to improve the quality of outcome data from clinical vaccine trials in pregnant women with a specific focus on the needs and requirements for safety monitoring in LMIC. In the first year of the project, a large and functional network of experts was created. The first outputs include a guidance document for clinical trials of immunization in pregnancy, a basic data collection guide, ten case definitions of key obstetric and neonatal health outcomes, an ontology of key terms and a map of pertinent disease codes. The GAIA Network is designed as an open and growing forum for professionals sharing the GAIA vision and aim. Based on the initial achievements, tools and services are developed to support investigators and strengthen immunization in pregnancy programs with specific focus on LMIC.
UR - http://www.scopus.com/inward/record.url?scp=84991199818&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2016.07.006
DO - 10.1016/j.vaccine.2016.07.006
M3 - Article
C2 - 27751641
AN - SCOPUS:84991199818
SN - 0264-410X
VL - 34
SP - 5993
EP - 5997
JO - Vaccine
JF - Vaccine
IS - 49
ER -